After-Hours Stock Movers 02/20: (ZIXI) (EHTH) (DBX) Higher (EYPT) (TRUE) (FSLR) Lower (more...)

After-Hours Stock Movers

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) 18.5% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

TrueCar (NASDAQ: TRUE) 18.2% LOWER; reported Q4 EPS of ($0.01), $0.03 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $89.7 million versus the consensus estimate of $88.05 million. TrueCar sees Q1 2020 revenue of $87-89 million, versus the consensus of $86.92 million. TrueCar sees FY2020 revenue of $335-355 million, versus the consensus of $367.46 million.

DMC Global (NASDAQ: BOOM) 18% LOWER; reported Q4 EPS of $0.65, $0.20 better than the analyst estimate of $0.45. Revenue for the quarter came in at $86.4 million versus the consensus estimate of $83.61 million.

ZixCorp (NASDAQ: ZIXI) 15.1% HIGHER; reported Q4 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $50.4 million versus the consensus estimate of $49.55 million. ZixCorp sees Q1 2020 EPS of $0.12-$0.13, versus the consensus of $0.12. ZixCorp sees Q1 2020 revenue of $52.2-52.7 million, versus the consensus of $50.23 million. ZixCorp sees FY2020 EPS of $0.56-$0.58, versus the consensus of $0.56. ZixCorp sees FY2020 revenue of $220-225 million, versus the consensus of $211.41 million.

First Solar (NASDAQ: FSLR) 14.2% LOWER; reported Q4 EPS of $1.48, $1.24 worse than the analyst estimate of $2.72. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.75 billion.

eHealth (NASDAQ: EHTH) 13.8% HIGHER; reported Q4 EPS of $4.13, $1.70 better than the analyst estimate of $2.43. Revenue for the quarter came in at $301.7 million versus the consensus estimate of $234.86 million. eHealth sees FY2020 EPS of $3.56-$4.09, versus the consensus of $3.01. eHealth sees FY2020 revenue of $580-620 million, versus the consensus of $546.02 million.

Dropbox (NASDAQ: DBX) 13.5% HIGHER; reported Q4 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $446 million versus the consensus estimate of $443.41 million.

Agile Therapeutics, Inc. (Nasdaq: AGRX) 13.4% LOWER; announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Conduent Incorporated (NASDAQ: CNDT) 12.1% LOWER; reported Q4 EPS of $0.18, $0.02 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.08 billion.

Zscaler (NASDAQ: ZS) 11% LOWER; reported Q2 EPS of $0.09, $0.06 better than the analyst estimate of $0.03. Revenue for the quarter came in at $101.3 million versus the consensus estimate of $98.97 million. Zscaler sees Q3 2020 EPS of $0.01-$0.03, versus the consensus of $0.04. Zscaler sees Q3 2020 revenue of $105-107 million, versus the consensus of $104.6 million. Zscaler sees FY2020 EPS of $0.14-$0.16, versus the consensus of $0.15. Zscaler sees FY2020 revenue of $414-417 million, versus the consensus of $410.38 million.

Ducommun Inc. (NYSE: DCO) 10% HIGHER; reported Q4 EPS of $0.80, $0.15 better than the analyst estimate of $0.65. Revenue for the quarter came in at $186.9 million versus the consensus estimate of $184.58 million.

National CineMedia (NASDAQ: NCMI) 8% HIGHER; reported Q4 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $147.2 million versus the consensus estimate of $140.08 million. National CineMedia sees FY2020 revenue of $450-465 million, versus the consensus of $452.53 million.

GENFIT (Nasdaq: GNFT) 7.8% LOWER; today announced that unblinding of the Phase 3 RESOLVE-IT data will be delayed to incorporate the latest FDA insights expected by the end of March. Topline interim results will be announced in the weeks following receipt of FDA insight.

BioSig Technologies, Inc. (Nasdaq: BSGM) 7.8% LOWER; announced that it intends to offer shares of its common stock in a 'best efforts' underwritten public offering.

Texas Roadhouse (NASDAQ: TXRH) 7.2% HIGHER; reported Q4 EPS of $0.61, $0.09 better than the analyst estimate of $0.52. Revenue for the quarter came in at $725.2 million versus the consensus estimate of $714.04 million. Comparable restaurant sales increased 4.4% at company restaurants and 3.4% at domestic franchise restaurants.

Builders FirstSource (NASDAQ: BLDR) 7% LOWER; reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.76 billion.

Nabors Industries (NYSE: NBR) 5.3% LOWER; reported Q4 EPS of ($0.77), $0.50 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $715.77 million versus the consensus estimate of $746.11 million.

Globant (NYSE: GLOB) 5% HIGHER; reported Q4 EPS of $0.64, $0.03 better than the analyst estimate of $0.61. Revenue for the quarter came in at $184.3 million versus the consensus estimate of $183.16 million. Globant sees Q1 2020 EPS of at least $0.62, versus the consensus of $0.60. Globant sees Q1 2020 revenue of at least $188 million, versus the consensus of $181.84 million. Globant sees FY2020 EPS of at least $2.74, versus the consensus of $2.74. Globant sees FY2020 revenue of at least $810 million, versus the consensus of $809.41 million.

Sprouts Farmers Market (NASDAQ: SFM) 5% HIGHER; reported Q4 EPS of $0.27, $0.14 better than the analyst estimate of $0.13. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.36 billion. Sprouts Farmers Market sees Q1 2020 EPS of $0.45-$0.47, versus the consensus of $0.46. Sprouts Farmers Market sees FY2020 EPS of $1.17-$1.23, versus the consensus of $1.12.

Celldex Therapeutics (NASDAQ: CLDX) 4% HIGHER; Cantor Fitzgerald initiates coverage on with a Overweight rating and a price target of $8.00.

Boyd Gaming (NYSE: BYD) 3.8% LOWER; reported Q4 EPS of $0.50, versus analyst estimate of $0.47. Revenue for the quarter came in at $833.1 million versus the consensus estimate of $825.64 million. Total Adjusted EBITDAR(1) was $227.6 million in the fourth quarter of 2019, up 9.1% from $208.6 million in the fourth quarter of 2018.

You May Also Be Interested In

• After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
• After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
• Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada